The role of osteopontin in tumor metastasis

被引:398
作者
Wai, PY [1 ]
Kuo, PC [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
关键词
osteopontin; metastasis; cancer; CD44; alpha(v)beta(3) integrin; transcription;
D O I
10.1016/j.jss.2004.03.028
中图分类号
R61 [外科手术学];
学科分类号
摘要
Osteopontin (OPN) is a glyco-phosphoprotein that is expressed and secreted by numerous human cancers. OPN functions in cell adhesion, chemotaxis, macrophage-directed interleukin-10 (IL-10) suppression, stress-dependent angiogenesis, prevention of apoptosis, and anchorage-independent growth of tumor cells by regulating cell-matrix interactions and cellular signaling through binding with integrin and CD44 receptors. While constitutive expression of OPN exists in several cell types, induced expression has been detected in T-lymphocytes, epidermal cells, bone cells, macrophages, and tumor cells in remodeling processes such as inflammation, ischemia-reperfusion, bone resorption, and tumor progression. Recently, substantial evidence has linked OPN with the regulation of metastatic spread by tumor cells. However, the molecular mechanisms that define the role of OPN in tumor metastasis are incompletely understood. Transcriptional regulators that contribute to the induction of OPN expression have received significant attention as potential modulators of the OPN-mediated metastatic phenotype. The following review will discuss the molecular structure of OPN, the evidence for its functional role in tumor cell metastasis, the downstream signals that activate invasive mechanisms, and the recent reports concerning regulation of OPN transcription. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:228 / 241
页数:14
相关论文
共 219 条
[1]   Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells [J].
Adwan, H ;
Bäuerle, TJ ;
Berger, MR .
CANCER GENE THERAPY, 2004, 11 (02) :109-120
[2]  
Agrawal D, 2002, J NATL CANCER I, V94, P513
[3]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[4]  
2-Z
[5]   Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators [J].
Angelucci, A ;
Festuccia, C ;
D'Andrea, G ;
Teti, A ;
Bologna, M .
BIOLOGICAL CHEMISTRY, 2002, 383 (01) :229-234
[6]   REGULATION OF THE JUNB GENE BY V-SRC [J].
APEL, I ;
YU, CL ;
WANG, T ;
DOBRY, C ;
VANANTWERP, ME ;
JOVE, R ;
PROCHOWNIK, EV .
MOLECULAR AND CELLULAR BIOLOGY, 1992, 12 (08) :3356-3364
[7]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[8]   Identification and characterization of high glucose and glucosamine responsive element in the rat osteopontin promoter [J].
Asaumi, S ;
Takemoto, M ;
Yokote, K ;
Ridall, AL ;
Butler, WT ;
Fujimoto, M ;
Kobayashi, K ;
Kawamura, H ;
Take, A ;
Saito, Y ;
Mori, S .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2003, 17 (01) :34-38
[9]   Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity [J].
Ashkar, S ;
Weber, GF ;
Panoutsakopoulou, V ;
Sanchirico, ME ;
Jansson, M ;
Zawaideh, S ;
Rittling, SR ;
Denhardt, DT ;
Glimcher, MJ ;
Cantor, H .
SCIENCE, 2000, 287 (5454) :860-864
[10]  
Asosingh K, 2000, CANCER RES, V60, P3096